Low-density lipoprotein cholesterol levels and adverse clinical outcomes in chronic kidney disease: Results from the KNOW-CKD
Nutrition, Metabolism & Cardiovascular Diseases Oct 18, 2021
Lee C, Park JT, Kang EW, et al. - In chronic kidney disease (CKD), a graded association between low-density lipoprotein cholesterol (LDL-C) and the risk of adverse cardiovascular outcome was identified. LDL-C <70 mg/dL was associated with the lowest risk, indicating that a lower LDL-C target may be acceptable.
This study involved 1,886 patients from the KoreaN cohort study for Outcome in patients With CKD (KNOW-CKD).
Extended major cardiovascular events (eMACEs) (primary outcome) and all-cause mortality, and CKD progression (secondary outcomes) were assessed.
For LDL-C categories of 70–99, 100–129, and ≥130 mg/dL, the estimated hazard ratios were 2.06, 2.79, and 4.10, respectively, relative to LDL-C <70mg/dL.
Renal function influenced the predictive performance of LDL-C for eMACEs.
Significantly higher risks of CKD progression were found in relation to higher LDL-C levels.
However, LDL-C level was not related to all-cause mortality.
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty
-
Paid Market Research Surveys
-
Case discussions, News & Journals' summaries